Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Delaware: - Beebe Medical Center — Lewes, Delaware
- Beebe South Coastal Health Campus — Millville, Delaware
- Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Delaware: - Beebe South Coastal Health Campus — Millville, Delaware
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- Beebe Health Campus — Rehoboth Beach, Delaware
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Delaware: - Research Site — Newark, Delaware
Phase 3 Recruiting Industry
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…
Sponsor: AstraZeneca
NCT ID: NCT06764875
Sites in Delaware: - Research Site — Newark, Delaware
Phase 2 Recruiting Industry
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastri…
Sponsor: AstraZeneca
NCT ID: NCT07069712
Sites in Delaware: - Research Site — Newark, Delaware
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Delaware: - Christiana Care Helen F. Graham Cancer Center — Newark, Delaware
Phase 1 Recruiting Industry
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Sponsor: Schrödinger, Inc.
NCT ID: NCT05544019
Sites in Delaware: - Christiana Care Hospital - Helen F Graham Cancer Center — Newark, Delaware
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Delaware: - Beebe South Coastal Health Campus — Frankford, Delaware
- Beebe Medical Center — Lewes, Delaware
- Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Delaware: - Beebe Medical Center — Lewes, Delaware
- Beebe South Coastal Health Campus — Millville, Delaware
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- Christiana Care Health System-Christiana Hospital — Newark, Delaware
NA Recruiting Academic/Other
This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic te…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07091617
Sites in Delaware: - Alfred I duPont Hospital for Children — Wilmington, Delaware
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Delaware: - Massive Bio SYNERGY-AI site — Newark, Delaware